Publications in collaboration with researchers from Oklahoma State University (1)

2008

  1. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

    Arthritis and Rheumatism, Vol. 58, Núm. 10, pp. 2968-2980